'Govt kept same rules for Indian, foreign cos while getting Covid vaccines'

Mandaviya also said that it was wrong to suggest that India stopped foreign made vaccines like that made by Moderna and Pfizer from coming to India

Mansukh Mandaviya
Union Health Minister Mansukh L Mandaviya
Press Trust of India New Delhi
4 min read Last Updated : Jun 25 2023 | 1:26 PM IST

Foreign-made vaccines were not procured during the Covid pandemic as the firms were demanding indemnity, which was not made available to Indian vaccine manufacturers, Union Health Minister Mansukh Mandaviya has said, asserting that the "same rule applies for all".

He also said that it was wrong to suggest that India stopped foreign made vaccines like that made by Moderna and Pfizer from coming to India.

"We may have certain requirements and strengths and other countries may have some other strengths and needs. It is wrong to say that India stopped any country from coming to India.When they applied with required data, we gave them emergency use approvals just like we gave to Indian companies," Mandaviya said in an exclusive interview to PTI recently.

However, their demands for indemnification and sovereign immunity waivers were a major impediment and eventually the government did not go ahead with it, the minister stated.

"At that time, Sputnik vaccine was also there and so were Indian vaccines. Whichever global company wants to come to India, they can come and sell their products, whether they are medicines or vaccines, we have no problem with that. But all need to follow India's rules and regulations. Our own companies did not ask for an indemnity. Sputnik did not ask for it," Mandaviya said.

"If our own companies are not seeking such relaxations and following our rules and regulations, then it is natural that global companies also do the same," he said.

The minister stressed that countries need to cooperate with each other in the health sector in times of globalisation.

Highlighting that India wants to expand its relationship with the world in the pharma and health sectors, Mandaviya said, "We are not against anyone or in favour of anyone".

India is such a country that applies the same rules and regulations for Indian and foreign companies with equal rights.

"Not many countries give such equal rights, but India does. The world also appreciates this position of our country," Mandaviya stated.

Recounting the fight against the pandemic, Mandaviya, who took charge of the health ministry in the middle of the coronavirus crisis in July 2021, said Covid management was a big challenge for a vast and diverse country like India, but its success story has now become an example for the entire world.

The minister also dismissed suggestions that approvals for vaccines were rushed without taking into account long-term side effects and that the recent spate of heart attacks was linked to it, saying the entire process from vaccine research to its administration followed all established international standards.

He said vaccine development and approvals used to take much longer earlier due to various physical and manual processes but the authorities and scientists made full use of the latest technology, including artificial intelligence, this time and, therefore, the entire process could be fast-tracked.

Mandaviya, a BJP leader from Gujarat known to enjoy the trust of Prime Minister Narendra Modi, said, "Let me tell you that PM Modi followed scientific ways for all procedures from the very beginning, from Covid management to vaccine research to approvals to the vaccination drive."

"It was the PM's direction because of which INSACOG (Indian SARS-CoV-2 Genomics Consortium) and several other taskforce and empowered groups were set up for vaccine approvals and other protocols. In the entire Covid journey, we followed scientific ways to fight this pandemic.

"Scientists told us when the vaccines should be approved, and the entire data and data analysis was done as per international standards. India followed the same international standards that were followed by global companies," he said.

The minister said it all indeed happened very fast in India but those questioning the speed must understand why the approvals came early.

"The times have changed. Earlier, data would get collected, their physical analysis would take place, and a lot of procedures would happen manually, but today we have artificial intelligence, the latest modelling methods, and digital technology, and we thought how can we speed up things by using all of these," he said.

"Whatever international practice is there for vaccine research and vaccine approval, India followed the same. India's vaccines are now known as the best in the world as they not only saved India but helped save the rest of the world also. Not just one, but five Indian-researched and manufactured vaccines are in the market today. Our vaccination journey has been based on scientific data while following all scientific protocols and methods, that I can assure you," he said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Mansukh Lal MandaviyaCoronavirus VaccinePfizer

First Published: Jun 25 2023 | 1:26 PM IST

Next Story